The purpose of this memo is to provide North Carolina Immunization Program (NCIP) providers with the latest information on the 2025-2026 COVID-19 vaccine. Please take time to carefully review this memo in full. COVID-19 vaccines for VFC-eligible patients are now available to order through NCIR.
Press Releases
Download the 2025 Annual Child care Immunization Report Memo
This email is to inform you that the North Carolina Immunization Program (NCIP) has opened applications for birthing hospitals interested in participating in the replacement model for birth dose Hepatitis B and RSV.
The purpose of this email is to inform VFC-enrolled providers that the RSV monoclonal antibody product clesrovimab (trade name ENFLONSIA™ manufactured by Merck) is now available for ordering. VFC doses will begin shipping after Oct. 2, 2025.Clesrovimab UseClesrovimab is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants under 8 months of age who are born during or entering their first RSV season and who are not protected through maternal RSV vaccination.
Download The 2025 LHD Annual Immunization Assessment MemoThe purpose of this memo is to remind local health department (LHD) staff about the upcoming 2025 Annual Immunization Assessment. This assessment will review NCIR records of children, 24 through 35 months old, who are labeled "active" in NCIR under the LHD site, as well as all children that live in the county.
All North Carolina public schools, including public charter schools are required annually to report on the status of Health Assessments for those students who are enrolling for the first time in a North Carolina public or public charter school (§ 130A-441(c) PDF, and the immunization status of all students in kindergarten, seventh, and twelfth grade (G.S. 130A-155(c) PDF).
Annual Health Assessment and Compliance Repo
Dear Local Health Department Partner,This email is to inform you that the North Carolina Immunization Program (NCIP) has doses of 317 VFA ABRYSVO® vaccine available for order for non-Medicaid, uninsured pregnant women between 32 to 36 weeks of gestation during September through January, who are receiving services at the local health department.ABRYSVO® administrations to pregnant individuals began on September 1, 2025, for the current RSV season.
"NCIP seeks nominations for the Samuel L. Katz, M.D. Excellence in Immunization Award; submit by Oct. 31, 2025."
Dear Providers,On Wednesday, Aug. 27, 2025, FDA approved the updated 2025-2026 COVID-19 vaccines and rescinded Emergency Use Authorizations (EUA) for previously authorized COVID-19 vaccines.As a result of the 2024–2025 COVID-19 EUA rescissions, providers are required to stop using those vaccine products or presentations immediately. Any COVID-19 vaccine products that were authorized under an EUA should be removed from storage, removed in NCIR as wasted, and returned per routine NCIP vaccine wastage guidelines.